Aug. 21, 2007
Epitomics Patent for "An Immortalized Mammal Hybridoma Fusion Partner" allowed in Canada.
Burlingame, CA. -
Epitomics Inc. today announced that the company's Canadian Patent Application No. 2,214,018 "An Immortalized Mammal Hybridoma Fusion Partner" has been allowed by the Canadian Intellectual Property Office.
The scheduled issue date for the patent is September 25, 2007. "We are very please by the allowance of this patent in Canada. It provides further validation and recognition for Epitomics proprietary RabMAb™ technology developed by Dr. Knight", said Dr. Guo-Liang Yu, President and CEO.
About Epitomics
Epitomics, Inc. is a biotechnology company that develops and commercializes monoclonal antibody technologies to accelerate the drug discovery. It provides services and products to support the reagent, diagnostic and therapeutic markets by utilizing its proprietary rabbit monoclonal antibody technologies. The company has headquarters in Burlingame, California.
|
